Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 21071684)

1.

Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants.

El-Khuffash AF, Slevin M, McNamara PJ, Molloy EJ.

Arch Dis Child Fetal Neonatal Ed. 2011 Mar;96(2):F133-7. doi: 10.1136/adc.2010.185967. Epub 2010 Nov 11.

PMID:
21071684
2.

Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage.

El-Khuffash A, Barry D, Walsh K, Davis PG, Molloy EJ.

Arch Dis Child Fetal Neonatal Ed. 2008 Nov;93(6):F407-12. doi: 10.1136/adc.2007.133140. Epub 2008 Feb 19.

PMID:
18285375
3.

Cardiac troponin T and N-terminal-pro-B type natriuretic peptide reflect myocardial function in preterm infants.

El-Khuffash A, Davis PG, Walsh K, Molloy EJ.

J Perinatol. 2008 Jul;28(7):482-6. doi: 10.1038/jp.2008.21. Epub 2008 Mar 6.

PMID:
18322550
4.

Plasma C-terminal pro-endothelin-1 and the natriuretic pro-peptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus.

Letzner J, Berger F, Schwabe S, Benzing J, Morgenthaler NG, Bucher HU, Bührer C, Arlettaz R, Wellmann S.

Neonatology. 2012;101(2):116-24. doi: 10.1159/000330411. Epub 2011 Sep 23.

PMID:
21952518
5.

Early N-terminal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants.

Ramakrishnan S, Heung YM, Round J, Morris TP, Collinson P, Williams AF.

Acta Paediatr. 2009 Aug;98(8):1254-9. doi: 10.1111/j.1651-2227.2009.01315.x. Epub 2009 Apr 30.

PMID:
19432837
6.

Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants.

Puddy VF, Amirmansour C, Williams AF, Singer DR.

Clin Sci (Lond). 2002 Jul;103(1):75-7.

PMID:
12095406
7.

N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus.

Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran JD.

Arch Dis Child Fetal Neonatal Ed. 2008 Jul;93(4):F257-60. doi: 10.1136/adc.2007.120691. Epub 2008 Jan 24.

PMID:
18218660
8.

Aminoterminal B-type natriuretic peptide (NT-proBNP) in the therapy of patent ductus arteriosus.

Bagnoli F, Rossetti A, Casucci M, Mori A.

Minerva Pediatr. 2010 Jun;62(3 Suppl 1):67-70.

PMID:
21089722
9.

Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants.

Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, Lee JW.

Pediatrics. 2005 Mar;115(3):e255-61. Epub 2005 Feb 1.

PMID:
15687418
10.

Influence of a patent ductus arteriosus on cardiac troponin T levels in preterm infants.

El-Khuffash AF, Molloy EJ.

J Pediatr. 2008 Sep;153(3):350-3. doi: 10.1016/j.jpeds.2008.04.014. Epub 2008 Jun 2.

PMID:
18534211
11.

How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude?

Chen S, Tacy T, Clyman R.

J Perinatol. 2010 Dec;30(12):780-5. doi: 10.1038/jp.2010.47. Epub 2010 Apr 8.

PMID:
20376057
12.

Plasma biomarkers and echocardiographic indices of left ventricular function in very low birth weight infants.

Perugu S, Rehan VK, Chow SL, Baylen B.

J Neonatal Perinatal Med. 2014 Jan 1;7(3):213-22. doi: 10.3233/NPM-14814010.

PMID:
25322997
13.

N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants.

Nuntnarumit P, Khositseth A, Thanomsingh P.

J Perinatol. 2009 Feb;29(2):137-42. doi: 10.1038/jp.2008.185. Epub 2008 Nov 20.

PMID:
19020527
14.

Longitudinal changes of brain-type natriuretic peptide in preterm neonates.

da Graca RL, Hassinger DC, Flynn PA, Sison CP, Nesin M, Auld PA.

Pediatrics. 2006 Jun;117(6):2183-9.

PMID:
16740863
15.

Early NT-proBNP is able to predict spontaneous closure of patent ductus arteriosus in preterm neonates, but not the need of its treatment.

Martinovici D, Vanden Eijnden S, Unger P, Najem B, Gulbis B, Maréchal Y.

Pediatr Cardiol. 2011 Oct;32(7):953-7. doi: 10.1007/s00246-011-0020-y. Epub 2011 Jun 9.

PMID:
21656237
16.

Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review.

Kulkarni M, Gokulakrishnan G, Price J, Fernandes CJ, Leeflang M, Pammi M.

Pediatrics. 2015 Feb;135(2):e510-25. doi: 10.1542/peds.2014-1995. Epub 2015 Jan 19. Review.

PMID:
25601976
17.

Can early B-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants?

Lee JH, Shin JH, Park KH, Rhie YJ, Park MS, Choi BM.

Neonatology. 2013;103(2):118-22. doi: 10.1159/000343034. Epub 2012 Nov 24.

PMID:
23182972
18.

Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus.

Kalra VK, DeBari VA, Zauk A, Kataria P, Myridakis D, Kiblawi F.

Ann Clin Lab Sci. 2011 Spring;41(2):131-7.

PMID:
21844570
19.

B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus.

Hsu JH, Yang SN, Chen HL, Tseng HI, Dai ZK, Wu JR.

J Pediatr. 2010 Jul;157(1):79-84. doi: 10.1016/j.jpeds.2009.12.045. Epub 2010 Mar 15.

PMID:
20227723
20.

B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus.

Attridge JT, Kaufman DA, Lim DS.

Arch Dis Child Fetal Neonatal Ed. 2009 May;94(3):F178-82. doi: 10.1136/adc.2008.147587. Epub 2008 Nov 3.

PMID:
18981033
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk